Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV ISIN · CA09076M2004 LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2022-02-10 Regulatory Filings
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2022-02-10 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a non-brokered private placement by BioVaxys Technology Corp. It details the terms of the private placement, including the number of units, price, warrants, and intended use of proceeds. There is no financial report, earnings data, or management discussion of financial results. The content focuses on fundraising activity and capital structure changes. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is over 6,000 characters, indicating it is a full announcement rather than a brief notice or report publication announcement.
2022-02-08 English
News release - English.pdf
Regulatory Filings
2021-12-07 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that BioVaxys' Chief Medical Officer has been invited to submit a scientific review article to a peer-reviewed journal. It discusses scientific and clinical developments, patent portfolio, and upcoming clinical studies. There is no indication of financial data, regulatory filings, voting results, or any formal report such as an annual or interim report. The document is a corporate announcement related to scientific and clinical progress, not a financial or regulatory filing. Therefore, it best fits the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2021-11-18 English
News release - English.pdf
Regulatory Filings
2021-11-17 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the results of an in vivo animal study demonstrating the safety and tolerability of a diagnostic product (CoviDTH) developed by BioVaxys Technology Corp. It discusses preclinical research findings, regulatory interactions with the FDA, and plans for clinical development. There are no financial statements, earnings data, or detailed management analysis. The content is primarily an update on clinical development progress and safety data, typical of a regulatory or corporate announcement rather than a formal financial or management report. The document length is 8659 characters, which is relatively short and consistent with a press release. It does not contain financial data or detailed report content, nor does it announce voting results, board changes, or capital structure changes. Therefore, the best fitting category is Regulatory Filings (RNS), as it is a general regulatory announcement about clinical study results and development plans that do not fit other specific categories.
2021-11-09 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.